US · AGIO · BIOTECHNOLOGY
Agios Pharmaceuticals, Inc. (AGIO) intrinsic value and stock valuation
$27.60as of 2026-11-21 · Mkt cap 1.93B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Agios Pharmaceuticals, Inc. DCF and intrinsic value
InvestorsCraft values AGIO with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from AGIO’s statements →
Agios Pharmaceuticals, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $54M | $36.5M | $26.8M | $14.2M | $0.00 |
| Operating income | -$-472.13M | -$-425.74M | -$-391.49M | -$-389.05M | -$-378.42M |
| Net income | -$-412.78M | $673.7M | -$-352.09M | -$-231.8M | $1.6B |
| EPSd | -$-7.12M | $11.6M | -$-6.33M | -$-4.23M | $26.5M |
| Operating cash flow | -$-372.98M | -$-389.84M | -$-296.06M | -$-309.48M | -$-407.32M |
| Capital expenditure | -$-4.32M | -$-1.69M | -$-1M | -$-4.88M | -$-5.74M |
| Free cash flow | -$-377.29M | -$-391.53M | -$-297.06M | -$-314.36M | -$-413.06M |
| Total assets | $1.3B | $1.66B | $937.1M | $1.24B | $1.44B |
| Total debt | $40.2M | $57M | $72M | $85.7M | $97.1M |
| Net debt | -$-48.92M | -$-19.26M | -$-16.21M | -$-53.6M | -$-106.03M |
| Total equity | $1.19B | $1.54B | $811M | $1.1B | $1.29B |
| Cash and short-term investments | $854.4M | $893.7M | $776.9M | $783.1M | $1.02B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $54M | $36.5M | $26.8M | $14.2M | $0.00 |
| Cost of revenue | $11.5M | $4.17M | $9.5M | $1.7M | $18.8M |
| Gross profit | $42.5M | $32.3M | $17.3M | $12.5M | -$-18.78M |
| Research and development expenses | $334.4M | $301.3M | $288.9M | $279.9M | $257M |
| Selling, general and administrative expenses | $180.3M | $156.8M | $119.9M | $121.7M | $121.4M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | -$-18.78M |
| Operating expenses | $514.6M | $458.1M | $408.8M | $401.6M | $359.6M |
| Cost and expenses | $526.2M | $462.2M | $418.3M | $403.3M | $378.4M |
| Interest income | $56.4M | $48.1M | $33.3M | $12.8M | $840K |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $5.18M | $5.65M | $6.62M | $8.56M | $18.8M |
| Ebitda | -$-408.62M | $723.6M | -$-345.46M | -$-223.24M | -$-337.73M |
| Operating income | -$-472.13M | -$-425.74M | -$-391.49M | -$-389.05M | -$-378.42M |
| Total other income/expenses, net | $58.3M | $1.14B | $39.4M | $157.3M | $21.9M |
| Income before tax | -$-413.8M | $718M | -$-352.09M | -$-231.8M | -$-356.51M |
| Income tax expense | -$-1.02M | $44.2M | $0.00 | $0.00 | $0.00 |
| Net income | -$-412.78M | $673.7M | -$-352.09M | -$-231.8M | $1.6B |
| Weighted average shares outstanding | $58M | $56.8M | $55.7M | $54.8M | $60.5M |
| Weighted average diluted shares outstanding | $58M | $57.9M | $55.7M | $54.8M | $60.5M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $854.4M | $893.7M | $776.9M | $783.1M | $1.02B |
| Net receivables | $10.6M | $4.11M | $2.81M | $2.21M | $4.38M |
| Inventory | $32.9M | $27.6M | $19.1M | $8.49M | $0.00 |
| Total current assets | $942.1M | $965.6M | $833.8M | $832.8M | $1.06B |
| Property, plant and equipment, net | $41.2M | $54.6M | $69.8M | $88.1M | $104.2M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $310M | $638.3M | $29.4M | $313.9M | $266.4M |
| Total non-current assets | $355.2M | $697.6M | $103.3M | $406M | $373.5M |
| Total assets | $1.3B | $1.66B | $937.1M | $1.24B | $1.44B |
| Accounts payable | $18.4M | $16.6M | $9.78M | $18.6M | $16.7M |
| Short-term debt | $18.4M | $16.8M | $15M | $13.7M | $11.2M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $82.2M | $81.2M | $68M | $62.6M | $59.8M |
| Long-term debt | $21.8M | $40.2M | $57M | $72M | $85.9M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $21.9M | $41.1M | $58.1M | $75.3M | $85.9M |
| Capital lease obligations | $40.2M | $57M | $72M | $85.7M | $97.1M |
| Total liabilities | $104.1M | $122.2M | $126.1M | $137.9M | $145.8M |
| Common stock | $70K | $70K | $70K | $70K | $70K |
| Retained earnings | -$-561.71M | -$-148.92M | -$-822.65M | -$-470.56M | -$-238.76M |
| Accumulated other comprehensive income (loss) | $2.19M | -$-1.52M | -$-440K | -$-12.54M | -$-1.2M |
| Total equity | $1.19B | $1.54B | $811M | $1.1B | $1.29B |
| Total investments | $1.08B | $1.46B | $718.2M | $957.7M | $1.08B |
| Total debt | $40.2M | $57M | $72M | $85.7M | $97.1M |
| Net debt | -$-48.92M | -$-19.26M | -$-16.21M | -$-53.6M | -$-106.03M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-412.78M | $673.7M | -$-352.09M | -$-231.8M | -$-356.51M |
| Depreciation and amortization | $5.18M | $5.65M | $6.62M | $8.56M | $9.24M |
| Stock-based compensation | $52.6M | $42.9M | $44.8M | $49.3M | $53.5M |
| Change in working capital | -$-33.04M | -$-19.77M | -$-19.06M | -$-16.43M | -$-36.82M |
| Accounts receivable | -$-6.47M | -$-1.3M | -$-600K | -$-2.21M | -$-4.38M |
| Inventory | -$-5.3M | -$-8.54M | -$-10.58M | -$-8.49M | $0.00 |
| Accounts payable | $1.75M | $6.6M | -$-8.73M | $3.44M | $1.86M |
| Net cash provided by operating activities | -$-372.98M | -$-389.84M | -$-296.06M | -$-309.48M | -$-407.32M |
| Investments in property, plant and equipment | -$-4.32M | -$-1.69M | -$-1M | -$-4.88M | -$-5.74M |
| Acquisitions, net | $0.00 | $40K | $0.00 | $132.8M | $0.00 |
| Net cash used for investing activities | $377.2M | $363.4M | $239.6M | $243.3M | $1.25B |
| Common stock issued | $8.68M | $14.4M | $5.43M | $2.68M | $0.00 |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | -$-802.49M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $8.68M | $14.4M | $5.43M | $2.35M | -$-765.77M |
| Net change in cash | $12.9M | -$-11.96M | -$-51.05M | -$-63.87M | $75.7M |
| Cash at end of period | $89.1M | $76.3M | $88.2M | $139.3M | $203.1M |
| Operating cash flow | -$-372.98M | -$-389.84M | -$-296.06M | -$-309.48M | -$-407.32M |
| Capital expenditure | -$-4.32M | -$-1.69M | -$-1M | -$-4.88M | -$-5.74M |
| Free cash flow | -$-377.29M | -$-391.53M | -$-297.06M | -$-314.36M | -$-413.06M |
Line items
Line items
Line items
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
- CEO
- Brian Goff
- Employees
- 540
- Beta
- 0.54
Explore
Frequently asked questions
What is the intrinsic value of Agios Pharmaceuticals, Inc. (AGIO)?
Agios Pharmaceuticals, Inc. (AGIO) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is AGIO undervalued?
AGIO trades at a price of $27.60 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.